Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 10/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.60 |
| ▸ | ALB | P02768 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241624 | 0.87 | TSPO (0.65) | TSPOOPRK1ALB | |
| SCHEMBL2757574 | 0.84 | TSPO (0.70) | TSPOOPRK1ALB | |
| SCHEMBL2757573 | 0.84 | TSPO (0.63) | TSPOOPRK1ALB | |
| SCHEMBL244035 | 0.84 | TSPO (0.63) | TSPOOPRK1ALB | |
| SCHEMBL14542056 | 0.82 | TSPO (0.67) | TSPOOPRK1ALB | |
| SCHEMBL7575533 | 0.82 | TSPO (0.82) | TSPOOPRK1ALB | |
| SCHEMBL14542291 | 0.82 | TSPO (0.77) | TSPOOPRK1ALB | |
| SCHEMBL7566742 | 0.81 | TSPO (0.66) | TSPOOPRK1ALB | |
| SCHEMBL7574173 | 0.81 | TSPO (0.69) | TSPOOPRK1ALB | |
| Ammonia Solution, Strong SCHEMBL7569838 | 0.81 | TSPO (0.75) | TSPOOPRK1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102355899-B | For the radiolabeled pyridinyl derivatives of in-vivo imaging | GE HEALTHCARE LTD. (GB) | 2015-10-07 | — | — | CN | disclosed |
| EP-2408451-A2 | RADIOLABELLED PYRIDINYL DERIVATIVES FOR IN-VIVO IMAGING | GE Healthcare UK Limited (GB) | 2012-01-25 | — | — | EP | disclosed |
| US-20120003154-A1 | ARYLOXYANILIDE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20120003154-A1 | ARYLOXYANILIDE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20120003154-A1 | ARYLOXYANILIDE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| WO-2010106166-A2 | ARYLOXYANILIDE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010106166-A2 | ARYLOXYANILIDE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003154-A1 | ARYLOXYANILIDE DERIVATIVES | GABBR1, GABRA4, CNR1 | TSPO 43/4885OPRK1 57/4885ALB 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.